期刊文献+

生活方式干预联合二甲双胍治疗糖耐量异常合并代谢综合征的临床观察 被引量:3

暂未订购
导出
摘要 目的:观察生活方式干预联合二甲双胍治疗糖耐量异常(IGT)合并代谢综合征(MS)的效果.方法:IGT合并MS患者72例,给予生活方式干预,包括健康教育、低热量、低脂肪饮食和中等体力活动、戒烟、限酒,血压高者给予降压等,血脂异常者给予调脂,同时加用盐酸二甲双胍片250~500 mg(根据血糖监测结果调整药物剂量),3次/d,观察6个月。观察治疗前后体重指数(BMI)、血压、血糖、总胆固醇、甘油三酯等变化。结果:生活方式干预联合二甲双胍治疗后,BMI、血压、空腹血糖、总胆固醇、甘油三酯等指标均好于治疗前,经比较有统计学意义。结论:对IGT合并MS患者应用生活方式干预联合二甲双胍治疗,能有效控制病情的进展。
出处 《航空航天医学杂志》 2011年第12期1450-1451,共2页 Journal of Aerospace medicine
  • 相关文献

参考文献4

  • 1Grundy SM,Hansen B,Smith SC Jr,et al.Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and Blood Institute/American Diabetes Association conference on scientific issues related to management[].Circulation.2004
  • 2Lakka HM,Laaksonen DE,Lakka TA,et al.The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men[].The Journal of The American Medical Association.2002
  • 3孙冬玲,顾东风.代谢综合征的干预和转归[J].中国实用内科杂志,2008,28(11):907-909. 被引量:16
  • 4屈岭.临床应用二甲双胍的相关问题[J].中国全科医学(医生读者版),2009(2):36-37. 被引量:5

二级参考文献8

  • 1顾东风,Reynolds K,杨文杰,陈恕凤,吴锡桂,段秀芳,蒲晓东,徐丽华,吴先萍,陈祥福,魏仁敏,陈娜萦,吴天一,王礼桂,姚才良,牟建军,马义峰,王晓飞,Whelton P,何江.中国成年人代谢综合征的患病率[J].中华糖尿病杂志(1006-6187),2005,13(3):181-186. 被引量:581
  • 2Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Dia, betes Federation[J]. Diabet Med,2006,23(5) :469-480.
  • 3Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults:findings from the Third National Health, and Nutrition Examination Survey [ J ]. JAMA, 2002,287 ( 3 ) : 356 - 359.
  • 4Ritz E. Metabolic syndrome and kidney disease [ J ]. Blood Purif, 2008,26 ( 1 ) :59 - 62.
  • 5Bo S,Ciccone G,Baldi C,et al. Effectiveness of a lifestyle intervention on metabolic syndrome:a randomized controlled trial[ J]. J Gen Intern Med ,2007,22(12) :1695 -1703.
  • 6Howard BV, Manson JE, Stefanick ML, et al. Low,fat dietary pattern and weight change over 7 years:the Women's Health Initiative Dietary Modification Trial[ J]. JAMA ,2006,295 (1) :39 - 49.
  • 7Kahn SE, Haffner SM, Heise MA, et al. Glycemic durabihty of rosiglitazone, mefformin, or glyburide monotherapy [ J]. N Engl J Med,2006,355 ( 23 ) :2427 - 2443.
  • 8Ruilope LM, Despres JP, Scheen A, et al. Effect of rimonabant, on blood pressure in overweight/obese patients with/without comorbidities: analysis of pooled RIO study results [ J ]. J Hypertens, 2008,26(2) :357 - 367.

共引文献18

同被引文献13

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部